Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. - Wikidata - wikimedia - TriplyDB

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

http://www.wikidata.org/entity/Q34592273

about

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Progress toward overcoming hypoxia-induced resistance to solid tumor therapy CAR T Cell Therapy: A Game Changer in Cancer Treatment CAR T cells for solid tumors: armed and ready to go?Adoptive T-cell therapy for Leukemia Toxicities of Immunotherapy for the Practitioner Clinical application of adoptive T cell therapy in solid tumors Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models Toxicity and management in CAR T-cell therapy T-cell receptor gene therapy--ready to go viral?An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients Reversal of tumor immune inhibition using a chimeric cytokine receptor.Biopolymer implants enhance the efficacy of adoptive T-cell therapy.Engineered T cells for cancer treatment Adoptive cell transfer as personalized immunotherapy for human cancer.Versatile strategy for controlling the specificity and activity of engineered T cells.Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Improving the safety of cell therapy products by suicide gene transfer Adoptive T-cell therapy: adverse events and safety switches.Clinical application of genetically modified T cells in cancer therapy.Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity Reassessing target antigens for adoptive T-cell therapy.Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.Current advances in T-cell-based cancer immunotherapy The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors Seatbelts in CAR therapy: How Safe Are CARS?Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras

P2860

Q26753082-AC354250-1522-4BB5-A27A-98E50AFBE13D Q26773309-65C9174B-1F1E-44AE-A9E5-966F928F5D58 Q26796405-5D594204-A614-4854-AA82-DCD105844BC0 Q26822769-36B34434-8CC5-49A1-A57C-B7F0968E573C Q26825489-58DE6F92-9FE1-47BD-BFA1-459ADD5C2184 Q27006934-C6B83403-7A03-45F1-9AF3-3FD5800C3D9C Q27008140-50C99DF9-335D-43CA-A373-03926B9AB19D Q27011283-9490A9F2-DF9B-4916-AEB2-393131FBF1C2 Q27025300-F65F0B4B-4D88-415A-8050-604468831A7B Q27026961-3DC42A02-636B-4C99-A7DD-61C35EDC11E4 Q27339832-8E90F2EE-39E2-4FD9-A1E8-07A0DBF004A9 Q28075314-391D785C-0E2C-4F07-9EA4-76ED4CE554D5 Q28081611-C71B9176-1458-42DD-BFF1-5C3039CC860C Q28551080-7559BC12-5726-44CD-8ED9-C5273407E5F1 Q30313444-B0126E77-E557-45DE-8DBC-36A65F12C12B Q30580134-5D599BC6-4C55-41CD-9477-3CA5AF8E32F3 Q30614247-6193AAF8-9BC6-47ED-A0B7-B18F3F62C9C0 Q33578792-A8696113-5670-40CF-849B-5F00B0E93DDF Q34043643-2037BCF8-36C3-431A-9458-F9B4D92CA1E6 Q34045831-4C308FB8-E4B9-407C-82A6-C510ED928B3F Q34047878-EE0775C1-0F7D-4229-BB3C-FF1B8B33D5F8 Q34139613-887D45C9-5792-49FF-9DBA-FA517E379C5C Q34205181-CF29B5BD-43D3-45D6-A55E-04FD10F47AB1 Q34240799-BC8A86D9-90A3-4AC7-AD09-29E6113CD1D2 Q34309388-BE35566A-730F-45AB-A632-DE26CDBFBE30 Q34453846-6E30646B-AE62-4DA4-B0CB-8568C3B83790 Q34511623-DB6F3B5D-F332-49E2-A328-B4DA903BA1DF Q34511646-F922F9CE-B4DE-495C-9FF1-89E31B4B9C2D Q34765959-83B4557F-D885-41A7-A964-FAB56C9D9231 Q34789569-BBFB3F0D-B620-447D-806A-2A223E7CE954 Q35071430-2D5DE07F-1F5F-4950-9575-D2006B1B80B2 Q35215158-9FF04FF3-5D0F-4CD8-B496-7BDAEEE86FFF Q35538728-481EF3AC-1C07-45DB-9BA1-0F00C7E7084B Q35567765-292F91DC-3720-464B-BCE8-3477CE335107 Q35583414-0C68AA74-364D-4188-B9F7-F7B58633CB67 Q35690389-DC6F7C07-F853-4D02-948C-8287C1B3B9AC Q35818365-8B4FB945-6A47-4A37-BD9C-51496636A445 Q35980893-0281C165-CF84-4923-B6D0-4FCE918D83D8 Q36015721-6265FF33-BC6F-43F3-B9D0-5078958F0A6E Q36110284-BA2E3361-CBAE-4207-9003-7B891650F9F6

P2860

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

http://www.wikidata.org/entity/Q34592273

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Treatment of metastatic renal ...... agement of on-target toxicity.

@en

Treatment of metastatic renal ...... agement of on-target toxicity.

@nl

type

label

Treatment of metastatic renal ...... agement of on-target toxicity.

@en

Treatment of metastatic renal ...... agement of on-target toxicity.

@nl

prefLabel

Treatment of metastatic renal ...... agement of on-target toxicity.

@en

Treatment of metastatic renal ...... agement of on-target toxicity.

@nl

P1433

Q34592273-0CD2EC2A-1177-44F5-8B77-9888C95E4CCA

P1476

Q34592273-490C2A2A-0BEC-49F9-BEF1-C9A86D5FCBEE

P2093

Q34592273-020F2239-6894-4B6A-BC22-B3F1C5F60B7F

Q34592273-23B18468-58FF-4734-B0CD-32C262D362A8

Q34592273-4A31054B-A36F-4A52-98C4-C4F392E83EB9

Q34592273-55929658-76DE-4786-A0AD-68665822253E

Q34592273-74048266-FF94-4C62-8506-4656E0278674

Q34592273-87E78E01-D5AE-4E4E-9A26-ADE0C3F5AA78

Q34592273-8984AAB5-CD62-4176-9E55-2A718952D0F7

Q34592273-A77C3F0E-FA70-418F-ADE5-214C2B0B0DC9

Q34592273-B1AD7240-DE06-4868-89F9-F3D5DC49A9F4

Q34592273-B526C5BC-D47F-4410-830B-7A8E4987924E

P2860

Q34592273-01451A7B-434C-49ED-92C4-DF7D6E54EBF5

Q34592273-01713DDB-8FE2-424B-8459-522D3AF0CA24

Q34592273-01D5CC49-8E53-40B1-9DAA-D09A17051C97

Q34592273-04EFF18B-252D-4A22-876B-91D50BB3A42B

Q34592273-0883ADBD-2A3D-437F-89C4-E8D558BA1D4B

Q34592273-16106250-135F-49CB-830D-D97883A33A12

Q34592273-1F593D4E-2002-46AF-8219-E20042B36692

Q34592273-2708B16E-2984-4726-B2C9-56C6363F2211

Q34592273-296A3C96-91CE-431A-9291-33C412309BB2

Q34592273-29EB9E8D-0D63-4CAA-AA32-432FA256EB75

P304

Q34592273-F5B137FB-9DCC-47C7-B911-63FCB59EADDB

P31

Q34592273-ADF91115-C807-4288-B648-9FA166098B17

P356

Q34592273-CFA86700-F33D-46F2-8E18-D01E2CC4945F

P433

Q34592273-496D2516-6D90-4E28-9E12-CAE19921EE70

P478

Q34592273-E5765E08-0150-45DD-8DD5-EC22C4D13C88

P577

Q34592273-0BF1E923-B3C2-4D63-B2EF-7808A4BBF31E

P5875

Q34592273-3B2B52D2-DE54-44D3-BAE1-F6FC633B973F

P698

Q34592273-CF6730D2-7072-488C-BA85-DF18F90D8F00

P932

Q34592273-C39964CC-CAF7-4149-9594-F59F72F52787

P356

P1433

Molecular Therapy

P1476

Treatment of metastatic renal ...... agement of on-target toxicity.

@en

P2093

Arnold Vulto

http://www.w3.org/2001/XMLSchema#string

Brigitte van Krimpen

http://www.w3.org/2001/XMLSchema#string

Cor Hj Lamers

http://www.w3.org/2001/XMLSchema#string

Corrien Groot

http://www.w3.org/2001/XMLSchema#string

Egbert Oosterwijk

http://www.w3.org/2001/XMLSchema#string

Jan W Gratama

http://www.w3.org/2001/XMLSchema#string

Michael den Bakker

http://www.w3.org/2001/XMLSchema#string

Pascal van Elzakker

http://www.w3.org/2001/XMLSchema#string

Reno Debets

http://www.w3.org/2001/XMLSchema#string

Sabine van Steenbergen

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Cancer regression in patients after transfer of genetically engineered lymphocytes

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250

Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P304

904-912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2013.17

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235669618

http://www.w3.org/2001/XMLSchema#string

P698

23423337

http://www.w3.org/2001/XMLSchema#string

P932

5189272

http://www.w3.org/2001/XMLSchema#string